American Society of Hirudotherapy

Nosocomial Infections from Medicinal Leeches — Epidemiology and Prevention

First systematic investigation of Aeromonas infections following clinical leech use

Last Updated: March 18, 2026Reviewed by: ASH Editorial Board
Safety & Infection ControlSartor C et al. · Clinical Infectious Diseases, 2002

Summary

Systematic investigation of nosocomial infections caused by Aeromonas species following medicinal leech therapy. Characterized the clinical presentation, microbiological profile, and risk factors for infection, establishing the evidence base for routine antibiotic prophylaxis during leech therapy.

Why This Matters for Hirudotherapy

Foundational safety study that defined the Aeromonas infection risk and drove adoption of prophylactic antibiotic protocols. Directly informs current clinical guidelines requiring fluoroquinolone prophylaxis during leech therapy, now standard of care in microsurgery units.

Citation

Nosocomial Infections with Aeromonas hydrophila from Leeches

Sartor C et al. · Clinical Infectious Diseases, 2002

DOI

Added to ASH library: March 18, 2026 · Site last updated: March 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.